The deal will build on Johnson & Johnson’s 70-year experience in neuroscience. Specifically, the company now adds Intra-Cellular's CAPLYTA® to its drug portfolio. This is a once-daily pill that has received FDA approval to treat schizophrenia and is the only FDA-approved drug to treat depressive episodes associated with bipolar depression. CAPLYTA is currently being reviewed for additional indications.
However, the acquisition also gives Johnson & Johnson access to Intra-Cellular's promising clinical-stage pipeline that includes drugs to treat generalized anxiety disorder and the psychosis and agitation that can be part of Alzheimer’s disease.
